The role of mast cells in asthma

Prostaglandins Leukotrienes and Essential Fatty Acids

Volumn 69, Issue 2-3, 2003, Pages 195-205

  Boyce, Joshua A ^a  

^a NONE

Author keywords

Asthma; Leukotrienes; Mast cells; Stem cell factor

Indexed keywords

CYTOKINE;

ALLERGIC REACTION; ASTHMA; CELL FUNCTION; CELL HYPERPLASIA; CELL MATURATION; DISEASE EXACERBATION; HISTOLOGY; HUMAN; IMMUNOMODULATION; LOWER RESPIRATORY TRACT; MAST CELL; MICROORGANISM; MUCOSA; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SMOOTH MUSCLE; TH2 CELL; VASCULARIZATION;

EID: 0041573131     PISSN: 09523278     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0952-3278(03)00081-4     Document Type: Article

References (127)

1. S. Muro, E. Minshall, Q. Hamid, The pathology of chronic asthma, Clin. Chest Med. 21 (2000) 225-244.
2. H. Cain, Bronchoprovocation testing, Clin. Chest. Med. 22 (2001) 651-659.
3. K. Amin, D. Ludviksdottir, C. Janson, et al., Inflammation and structural changes in the airways of patients with atopic and nonatopic asthma. BHR Group, Am. J. Respir. Crit. Care Med. 162 (2000) 2295-2301.
4. R.L. Stevens, K.F. Austen, Recent advances in the cellular and molecular biology of mast cells, Immunol. Today 10 (1989) 381-386.
5. 2 metabolite 9 alpha, 11 beta-prostaglandin F2 after aspirin challenge supports mast cell activation in aspirin-induced airway obstruction, J. Allerg. Clin. Immunol. 98 (1996) 421-432.
6. 4 from mouse bone marrow-derived mast cells, J. Immunol. 130 (1983) 1885-1890.
7. R.A. Lewis, K.F. Austen, J.M. Drazen, et al., Slow-reacting substance of anaphylaxis: identification of leukotrienes c-1 and d from human and rat sources, Proc. Natl. Acad. Sci. USA 77 (1980) 3710-3714.
8. Y. Okayama, C. Petit-Frere, O. Kassel, et al., IgE-dependent expression of mRNA for IL-4 and IL-5 in human lung mast cells, J. Immunol. 155 (1995) 1796-1808.
9. H. Toru, R. Pawankar, C. Ra, J. Yata, T. Nakahata, Human mast cells produce IL-13 by high-affinity IgE receptor cross-linking: enhanced IL-13 production by IL-4-primed human mast cells, J. Allerg. Clin. Immunol. 102 (1998) 491-502.
10. H. Kobayashi, Y. Okayama, T. Ishizuka, et al., Production of IL-13 by human lung mast cells in response to Fcε receptor cross-linkage, Clin. Exp. Allerg. 28 (1998) 1219-1227.
11. A.L. Wright, Epidemiology of asthma and recurrent wheeze in childhood, Clin. Rev. Allerg. Immunol. 22 (2002) 33-44.
12. M.D. Inman, R. Watson, D.W. Cockcroft, et al., Reproducibility of allergen-induced early and late asthmatic responses, J. Allerg. Clin. Immunol. 95 (1995) 1191-1195.
13. M.C. Liu, W.C. Hubbard, D. Proud, et al., Immediate and late inflammatory responses to ragweed antigen challenge of the peripheral airways in allergic asthmatics. Cellular, mediator, and permeability changes, Am. Rev. Respir. Dis. 144 (1991) 51-58.
14. T.B. Casale, D. Wood, H.B. Richerson, et al., Direct evidence of a role for mast cells in the pathogenesis of antigen-induced bronchoconstriction, J. Clin. Invest. 80 (1987) 1507-1511.
15. G.M. Gauvreau, J.M. Lee, R.M. Watson, et al., Increased numbers of both airway basophils and mast cells in sputum after allergen inhalation challenge of atopic asthmatics, Am. J. Respir. Crit. Care Med. 161 (2000) 1473-1478.
16. A. Roquet, B. Dahlen, M. Kumlin, et al., Combined antagonism of leukotrienes and histamine produces predominant inhibition of allergen-induced early and late phase airway obstruction in asthmatics, Am. J. Respir. Crit. Care Med. 155 (1997) 1856-1863.
17. A. Hamilton, I. Faiferman, P. Stober, R.M. Watson, P.M. O'Byrne, Pranlukast, a cysteinyl leukotriene receptor antagonist, attenuates allergen-induced early and late-phase bronchoconstriction and airway hyperresponsiveness in asthmatic subjects, J. Allerg. Clin. Immunol. 102 (1998) 177-183.
18. J.V. Fahy, H.E. Fleming, H.H. Wong, et al., The effect of an anti-IgE monoclonal antibody on the early and late-phase responses to allergen inhalation in asthmatic subjects, Am. J. Respir. Crit. Care Med. 155 (1997) 1828-1834.
19. M. Humbert, S.R. Durham, S. Ying, et al., IL-4 and IL-5 mRNA and protein in bronchial biopsies from patients with atopic and nonatopic asthma: evidence against intrinsic asthma being a distinct immunopathologic entity, Am. J. Respir. Crit. Care Med. 154 (1996) 1497-1504.
20. F. Freymuth, A. Vabret, J. Brouard, et al., Detection of viral, Chlamydia pneumoniae and Mycoplasma pneumoniae infections in exacerbations of asthma in children, J. Clin. Virol. 13 (1999) 131-139.
21. L.A. Laitinen, A. Laitinen, T. Haahtela, Airway mucosal inflammation even in patients with newly diagnosed asthma, Am. Rev. Respir. Dis. 147 (1993) 697-704.
22. C.E. Brightling, P. Bradding, F.A. Symon, et al., Mast cell infiltration of airway smooth muscle in asthma, N. Engl. J. Med. 346 (2002) 1699-1705.
23. S. Page, A.J. Ammit, J.L. Black, C.L. Armour, Human mast cell and airway smooth muscle cell interactions: implications for asthma, Am. J. Physiol. - Lung Cell. Mol. Physiol. 281 (2001) L1313-323.
24. J.K. Brown, C.A. Jones, L.A. Rooney, G.H. Caughey, I.P. Hall, Tryptase's potent mitogenic effects in human airway smooth muscle cells are via nonproteolytic actions, Am. J. Physiol. - Lung Cell. Mol. Physiol. 282 (2002) L197-206.
25. A. Pesci, A. Foresi, G. Bertorelli, et al., Histochemical characteristics and degranulation of mast cells in epithelium and lamina propria of bronchial biopsies from asthmatic and normal subjects, Am. Rev. Respir. Dis. 147 (1993) 684-689.
26. N.G. Carroll, S. Mutavdzic, A.L. James, Distribution and degranulation of airway mast cells in normal and asthmatic subjects, Eur. Resp. J. 19 (2002) 879-885.
27. B.E. Heard, A. Dewar, A.J. Nunn, A.B. Kay, Heterogeneous ultrastructure of human bronchial mast cells: morphometric subdivision of cell types and evidence for a degranulation gradient, Am. J. Respir. Cell. Mol. Biol. 3 (1990) 71-78.
28. 4 in bronchoalveolar lavage fluid from atopic asthmatics after endobronchial allergen challenge, Am. Rev. Respir. Dis. 142 (1990) 112-119.
29. P.S. Foster, S.P. Hogan, A.J. Ramsay, K.I. Matthaei, I.G. Young, Interleukin 5 deficiency abolishes eosinophilia, airways hyperreactivity, and lung damage in a mouse asthma model, J. Exp. Med. 183 (1996) 195-201.
30. D.B. Corry, H.G. Folkesson, M.L. Warnock, et al., Interleukin 4, but not interleukin 5 or eosinophils, is required in a murine model of acute airway hyperreactivity, J. Exp. Med. 183 (1996) 109-117.
31. N.W. Lukacs, A. John, A. Berlin, et al., E- and p-selectins are essential for the development of cockroach allergen-induced airway responses, J. Immunol. 169 (2002) 2120-2125.
32. K. Sadakane, T. Ichinose, H. Takano, et al., Murine strain differences in airway inflammation induced by diesel exhaust particles and house dust mite allergen, Int. Arch. Allerg. Immunol. 128 (2002) 220-228.
33. J.M. Schuh, C.A. Power, A.E. Proudfoot, et al., Airway hyperresponsiveness, but not airway remodeling, is attenuated during chronic pulmonary allergic responses to Aspergillus in CCR4-/- mice, FASEB J. 16 (2002) 1313-1315.
34. A. Mochizuki, N. Tamura, Y. Yatabe, et al., Suppressive effects of F-1322 on the antigen-induced late asthmatic response and pulmonary eosinophilia in guinea pigs, Eur. J. Pharmacol. 430 (2001) 123-133.
35. D.S. Robinson, Q. Hamid, S. Ying, et al., Predominant TH2-like bronchoalveolar T-lymphocyte population in atopic asthma, N. Engl. J. Med. 326 (1992) 298-304.
36. K. Takeda, E. Hamelmann, A. Joetham, et al., Development of eosinophilic airway inflammation and airway hyperresponsiveness in mast cell-deficient mice, J. Exp. Med. 186 (1997) 449-454.
37. T. Kobayashi, T. Miura, T. Haba, et al., An essential role of mast cells in the development of airway hyperresponsiveness in a murine asthma model, J. Immunol. 164 (2000) 3855-3861.
38. C.M. Williams, S.J. Galli, Mast cells can amplify airway reactivity and features of chronic inflammation in an asthma model in mice, J. Exp. Med. 192 (2000) 455-462.
39. T.R. Martin, T. Takeishi, H.R. Katz, et al., Mast cell activation enhances airway responsiveness to methacholine in the mouse, J. Clin. Invest. 91 (1993) 1176-1182.
40. M. Rottem, T. Okada, J.P. Goff, D.D. Metcalfe, Mast cells cultured from the peripheral blood of normal donors and patients with mastocytosis originate from a CD34+/FcER1-population, Blood 84 (1994) 2489-2496.
41. A.S. Kirshenbaum, S.W. Kessler, J.P. Golf, D.D. Metcalfe, Demonstration of the origin of human mast cells from CD34+ bone marrow progenitor cells, J. Immunol. 146 (1991) 1410-1415.
42. A.S. Kirshenbaum, J.P. Goff, T. Semere, et al., Demonstration that mast cells arise from a progenitor cell population that is CD34+, c-kit+, and expresses aminopeptidase N (CD13), Blood 94 (1999) 2333-2342.
43. M.F. Gurish, H. Tao, J.P. Abonia, et al., Intestinal mast cell progenitors require CD49d/β7 (α4β7 integrin) for tissue-specific homing, J. Exp. Med. 194 (2001) 1243-1252.
44. Y. Kitamura, S. Go, K. Hatanaka, Decrease of mast cells in W/Wv mice and their increase by bone marrow transplantation, Blood 52 (1978) 447-452.
45. E.N. Geissler, M.A. Ryan, D.E. Housman, The dominant-white spotting (W) locus of the mouse encodes the c-kit proto-oncogene, Cell 55 (1988) 185-192.
46. E. Huang, K. Nocka, D.R. Beier, et al., The hematopoietic growth factor KL is encoded by the S1 locus and is the ligand of the c-kit receptor, the gene product of the W locus, Cell 63 (1990) 225-233.
47. Y. Kitamura, S. Go, Decreased production of mast cells in S1/S1d anemic mice, Blood 53 (1979) 492-497.
48. G. Nilsson, J.H. Butterfield, K. Nilsson, A. Siegbahn, Stem cell factor is a chemotactic factor for human mast cells, J. Immunol. 153 (1994) 3717-3723.
49. A. Lorentz, D. Schuppan, A. Gebert, M.P. Manns, S.C. Bischoff, Regulatory effects of stem cell factor and interleukin-4 on adhesion of human mast cells to extracellular matrix proteins, Blood 99 (2002) 966-972.
50. N.S. Yee, I. Paek, P. Besmer, Role of kit-ligand in proliferation and suppression of apoptosis in mast cells: basis for radio-sensitivity of white spotting and steel mutant mice, J. Exp. Med. 179 (1994) 1777-1787.
51. A.M.A. Irani, G. Nillson, U. Miettinen, et al., Recombinant human stem cell factor stimulates differentiation of mast cells from dispersed human fetal liver cells, Blood 80 (1992) 3009-3021.
52. H. Mitsui, T. Furitsu, A.M. Dvorak, et al., Development of human mast cells from umbilical cord blood cells by recombinant human and murine c-kit ligand, Proc. Natl. Acad. Sci. USA 90 (1993) 735-739.
53. B. Echtenacher, D.N. Mannel, L. Hultner, Critical protective role of mast cells in a model of acute septic peritonitis, Nature 381 (1996) 75-79.
54. R. Malaviya, T. Ikeda, E. Ross, S.N. Abraham, Mast cell modulation of neutrophil influx and bacterial clearance at sites of infection through TNF-alpha, Nature 381 (1996) 77-80.
55. R. Malaviya, Z. Gao, K. Thankavel, P.A. van der Merwe, S.N. Abraham, The mast cell tumor necrosis factor alpha response to FimH-expressing Escherichia coli is mediated by the glycosylphosphatidylinositol-anchored molecule CD48, Proc. Natl. Acad. Sci. USA 96 (1999) 8110-8115.
56. V. Supajatura, H. Ushio, A. Nakao, et al., Protective roles of mast cells against enterobacterial infection are mediated by toll-like receptor 4, J. Immunol. 167 (2001) 2250-2256.
57. J.L. Gommerman, D.Y. Oh, X. Zhou, et al., A role for CD21/CD35 and CD19 in responses to acute septic peritonitis: a potential mechanism for mast cell activation, J. Immunol. 165 (2000) 6915-6921.
58. V. Supajatura, H. Ushio, A. Nakao, et al., Differential responses of mast cell Toll-like receptors 2 and 4 in allergy and innate immunity, J. Clin. Invest. 109 (2002) 1351-1359.
59. E.A. Kurt-Jones, L. Popova, L. Kwinn, et al., Pattern recognition receptors TLR4 and CD14 mediate response to respiratory syncytial virus, Nat. Immunol. 1 (2000) 398-401.
60. K.L. Hoek, G.H. Cassell, L.B. Duffy, T.P. Atkinson, Mycoplasma pneumoniae-induced activation and cytokine production in rodent mast cells, J. Allerg. Clin. Immunol. 109 (2002) 470-476.
61. M. Bidri, I. Vouldoukis, M.D. Mossalayi, et al., Evidence for direct interaction between mast cells and Leishmania parasites, Parasite Immunol. 19 (1997) 475-483.
62. M. Hosoda, M. Yamaya, T. Suzuki, et al., Effects of rhinovirus infection on histamine and cytokine production by cell lines from human mast cells and basophils, J. Immunol. 169 (2002) 1482-1491.
63. W.J. Calhoun, C.A. Swenson, E.C. Dick, et al., Experimental rhinovirus 16 infection potentiates histamine release after antigen bronchoprovocation in allergic subjects, Am. Rev. Respir. Dis. 144 (1991) 1267-1273.
64. C. Huang, G.T. De Sanctis, P.J. O'Brien, et al., Evaluation of the substrate specificity of human mast cell tryptase beta I and demonstration of its importance in bacterial infections of the lung, J. Biol. Chem. 276 (2001) 26276-26284.
65. R. Malaviya, S. Abraham, Role of mast cell leukotrienes in neutrophil recruitment and bacterial clearance in infectious peritonitis, J. Leuk. Biol. 67 (2000) 841-846.
66. R. Blair, H. Meng, M. Marchese, et al., Human mast cells stimulate vascular tube formation. Tryptase is a novel, potent angiogenic factor, J. Clin. Invest. 99 (1997) 2691-2700.
67. J. Cairns, A. Walls, Mast cell tryptase is a mitogen for epithelial cells. Stimulation of IL-8 production and intercellular adhesion molecule-1 expression, J. Immunol. 156 (1996) 275-283.
68. J. Cairns, A. Walls, Mast cell tryptase stimulates the synthesis of type I collagen in human lung fibroblasts, J. Clin. Invest. 99 (1997) 1313-1321.
69. E. Garbuzenko, A. Nagler, D. Pickholtz, et al., Human mast cells stimulate fibroblast proliferation, collagen synthesis and lattice contraction: a direct role for mast cells in skin fibrosis, Clin. Exp. Allerg. 32 (2002) 237-246.
70. C. Noli, A. Miolo, The mast cell in wound healing, Veterinary Dermatol. 12 (2001) 303-313.
71. F.D. Finkelman, T. Shea-Donohue, J. Goldhill, et al., Cytokine regulation of host defense against parasitic gastrointestinal nematodes, Ann. Rev. Immunol. 15 (1997) 505-533.
72. E.J. Ruitenberg, A. Elgersma, Absence of intestinal mast cell response in congenitally athymic mice during Trichinella spiralis infection, Nature (Lond.) 264 (1976) 258-260.
73. A.M. Irani, S. Craig, G. DeBlois, et al., Deficiency of the tryptase-positive, chymase-negative mast cell type in gastrointestinal mucosa of patients with defective T lymphocyte function, J. Immunol. 138 (1987) 4381-4386.
74. C.S. Lantz, J. Boesiger, C.H. Song, et al., Role for interleukin-3 in mast cell and basophil development and in immunity to parasites, Nature (Lond.) 392 (1998) 90-93.
75. K.B. Madden, J.F. Urban Jr, H.J. Ziltener, et al., Antibodies to IL-3 and IL-4 suppress helminth-induced intestinal mastocytosis, J. Immunol. 147 (1991) 1387-1391.
76. U.A. Temann, G.P. Geba, J.A. Rankin, R.A. Flavell, Expression of interleukin 9 in the lungs of transgenic mice causes airway inflammation, mast cell hyperplasia, and bronchial hyperresponsiveness, J. Exp. Med. 188 (1998) 1307-1320.
77. D.S. Friend, N. Ghildyal, K.F. Austen, et al., Mast cells that reside at different locations in the jejunum of mice infected with Trichinella spiralis exhibit sequential changes in their granule ultrastructure and chymase phenotype, J. Cell. Biol. 135 (1996) 279-290.
78. N. Ghildyal, H.P. McNeil, S. Stechschulte, et al., IL-10 induces transcription of the gene for mouse mast cell protease-1, a serine protease preferentially expressed in mucosal mast cells of Trichinella spiralis-infected mice, J. Immunol. 149 (1992) 2123-2129.
79. P.A. Knight, S.H. Wright, C.E. Lawrence, Y.Y. Paterson, H.R. Miller, Delayed expulsion of the nematode Trichinella spiralis in mice lacking the mucosal mast cell-specific granule chymase, mouse mast cell protease-1, J. Exp. Med. 192 (2000) 1849-1856.
80. D.F. Anderson, J.D. MacLeod, S.M. Baddeley, et al., Seasonal allergic conjunctivitis is accompanied by increased mast cell numbers in the absence of leukocyte infiltration, Clin. Exp. Allerg. 27 (1997) 1060-1066.
81. K. Amin, J. Rinne, T. Haahtela, et al., Inflammatory cell and epithelial characteristics of perennial allergic and nonallergic rhinitis with a symptom history of 1 to 3 years' duration, J. Allerg. Clin. Immunol. 107 (2001) 249-257.
82. A. Straumann, M. Bauer, B. Fischer, K. Blaser, H.U. Simon, Idiopathic eosinophilic esophagitis is associated with a Th2-type allergic inflammatory response, J. Allerg. Clin. Immunol. 108 (2002) 954-961.
83. M. Yanagida, H. Fukamachi, K. Ohgami, et al., Effects of T-helper 2-type cytokines, interleukin-3 (IL-3), IL-4, IL-5, and IL-6 on the survival of cultured human mast cells, Blood 86 (1995) 3705-3714.
84. H. Ochi, W.M. Hirani, Q. Yuan, et al., T helper type-2 cytokine-mediated comitogenic responses and CCR3 expression during differentiation of human mast cells in vitro, J. Exp. Med. 190 (1999) 267-280.
85. S.C. Bischoff, G. Sellge, A. Lorentz, et al., IL-4 enhances proliferation and mediator release in mature human mast cells, Proc. Natl. Acad. Sci. USA 96 (1999) 8080-8085.
86. E. Noguchi, M. Shibasaki, M. Kamioka, et al., New polymorphisms of haematopoietic prostaglandin D synthase and human prostanoid DP receptor genes, Clin. Exp. Allerg. 32 (2002) 93-96.
87. H. Hirai, K. Tanaka, O. Yoshie, et al., Prostaglandin D2 selectively induces chemotaxis in T helper type 2 cells, eosinophils, and basophils via seven-transmembrane receptor CRTH2, J. Exp. Med. 193 (2001) 255-261.
88. 4 in normal and asthmatic subjects, Am. Rev. Respir. Dis. 135 (1987) 333-337.
89. 4 on the airways in asthma, N. Engl. J. Med. 308 (1983) 436-439.
90. 4 and granulocytic infiltration into asthmatic airways, Lancet 341 (1993) 989-990.
91. 4) in human skin, J. Invest. Derm. 80 (1983) 115-119.
92. 4, increase the release of mucous from human airways in vitro, Am. Rev. Respir. Dis. 126 (1982) 4449-4451.
93. W.R. Henderson Jr, L.O. Tang, S.J. Chu, et al., A role for cysteinyl leukotrienes in airway remodeling in a mouse asthma model, Am. J. Respir. Crit. Care Med. 165 (2002) 108-116.
94. K.R. Lynch, G.P. O'Neill, Q. Liu, et al., Characterization of the human cysteinyl leukotriene cysLT1 receptor, Nature 399 (1999) 789-793.
95. C.E. Heise, B.F. O'Dowd, D.J. Figueroa, et al., Characterization of the human cysteinyl leukotriene 2 receptor, J. Biol. Chem. 275 (2000) 30531-30536.
96. E. Israel, J. Cohn, L. Dube, J.M. Drazen, Effect of treatment with zileuton, a 5-lipoxygenase inhibitor, in patients with asthma A randomized controlled trial Zileuton Clinical Trial Group, JAMA 275 (1996) 931-936.
97. L.C. Altman, Z. Munk, J. Seltzer, et al., A placebo-controlled, dose-ranging study of montelukast, a cysteinyl leukotriene-receptor antagonist Montelukast Asthma Study Group, J. Allerg. Clin. Immunol. 102 (1998) 50-56.
98. D.J. Figueroa, R.M. Breyer, S.K. Defoe, et al., Expression of the cysteinyl leukotriene 1 receptor in normal human lung and peripheral blood leukocytes, Am. J. Respir. Crit. Care Med. 163 (2001) 226-233.
99. E.A. Mellor, A. Maekawa, K.F. Austen, J.A. Boyce, Cysteinyl leukotriene receptor 1 is also a pyrimidinergic receptor and is expressed by human mast cells, Proc. Natl. Acad. Sci. USA 98 (2001) 7964-7969.
100. E.A. Mellor, K.F. Austen, J.A. Boyce, Cysteinyl leukotrienes and uridine diphosphate induce cytokine generation by human mast cells through an interleukin 4-regulated pathway that is inhibited by leukotriene receptor antagonists, J. Exp. Med. 195 (2002) 583-592.
101. K. Minoguchi, Y. Kohno, H. Minoguchi, et al., Reduction of eosinophilic inflammation in the airways of patients with asthma using montelukast, Chest 121 (2002) 732-738.
102. I.D. Lawrence, J.A. Warner, V.L. Cohan, et al., Purification and characterization of human skin mast cells. Evidence for human mast cell heterogeneity, J. Immunol. 139 (1987) 3062-3069.
103. D.W. MacGlashan Jr, R.P. Schleimer, S.P. Peters, et al., Generation of leukotrienes by purified lung mast cells, J. Clin. Invest. 70 (1982) 747-751.
104. S.P. Peters, D.W. MacGlashan Jr, E.S. Schulman, et al., Arachidonic acid metabolism in purified human lung mast cells, J. Immunol. 132 (1984) 1972-1979.
105. C.C. Fox, A.M. Dvorak, S.P. Peters, A. Kagey-Sobotka, L.M. Lichtenstein, Isolation and characterization of human intestinal mucosal mast cells, J. Immunol. 135 (1985) 483-491.
106. W.A. Massey, C-.B. Guo, A.M. Dvorak, et al., Human uterine mast cells. Isolation, purification, characterization, ultrastructure, and pharmacology, J. Immunol. 147 (1991) 1621-1627.
107. 2+-dependent translocation domain with homology to PKC and GAP, Cell 65 (1991) 1043-1051.
108. R. Malavia, R. Malavia, B.A. Jakschik, Reversible translocation of 5-lipoxygenase in mast cells upon IgE/antigen stimulation, J. Biol. Chem. 268 (1993) 4939-4944.
109. R.A.F. Dixon, R.E. Diehl, E. Opas, et al., Requirement of a 5-lipoxygenase-activating protein for leukotriene biosynthesis, Nature 343 (1990) 282-284.
110. 4 hydrolase from rat neutrophils, Biochem. Biophys. Acta 840 (1985) 43-50.
111. 4, Proc. Natl. Acad. Sci. USA 91 (1994) 7663-7667.
112. 4, Proc. Natl. Acad. Sci. USA 89 (1992) 11598-11602.
113. M. Raulf, M. Stuning, W. Konig, Metabolism of leukotrienes by L-gamma-glutamyl-transpeptidase and dipeptidase from human polymorphonuclear granulocytes, Immunology 55 (1985) 135-147.
114. J.M. Drazen, C.N. Yandava, L. Dube, et al., Pharmacogenetic association between ALOX5 promoter genotype and the response to anti-asthma treatment, Nat. Genet. 22 (1999) 168-170.
115. 4 synthase: organization, nucleotide sequence, and chromosomal localization to 5q35, J. Biol. Chem. 271 (1996) 11356-11361.
116. 4 synthase due to overactive transcription of an allelic variant associated with aspirin-intolerant asthma, Am. J. Respir. Cell. Mol. Biol. 23 (2000) 290-296.
117. 4 synthase promoter polymorphism in Japanese patients with aspirin-induced asthma, J. Allerg. Clin. Immunol. 109 (2002) 936-942.
118. 4 synthase does not correlate with the aspirin-intolerant asthma phenotype in the United States, J. Allerg. Clin. Immunol. 106 (2000) 72-76.
119. 4 synthase allele modifies cysteinyl leukotriene synthesis in eosinophils and predicts clinical response to zafirlukast, Thorax 55 (Suppl 2) (2000) S28-31.
120. 4 synthase pathway in mouse mast cells, J. Biol. Chem. 270 (1995) 22653-22656.
121. 4 synthase expression by interleukin 4, J. Exp. Med. 193 (2001) 123-133.
122. H. Toru, C. Ra, S. Nonoyama, et al., Induction of the high-affinity IgE receptor (FcεRI) on human mast cells by IL-4, Int. Immunol. 8 (1996) 1367-1373.
123. S.C. Bischoff, G. Sellge, A. Lorentz, et al., IL-4 enhances proliferation and mediator release in mature human mast cells, Proc. Natl. Acad. Sci. USA 96 (1999) 8080-8085.
124. H. Ochi, N.H. De Jesus, F. Hsieh, K.F. Austen, J. Boyce, Interleukins 4 and 5 prime human mast cells for different profiles of IgE-dependent cytokine production, Proc. Natl. Acad. Sci. USA 97 (2000) 10509-10513.
125. H. Toru, T. Kinashi, C. Ra, et al., Interleukin-4 induces homotypic aggregation of human mast cells by promoting LFA-1/ICAM-1 adhesion molecules, Blood 89 (1997) 3296-3302.
126. H. Milgrom, R.B. Fick, J.Q. Su, et al., Treatment of allergic asthma with monoclonal anti-IgE antibody rhuMAb-E25 Study Group, N. Engl. J. Med. 341 (1999) 1966-1973.
127. M.K. Church, J.O. Warner, Sodium cromoglycate and related drugs, Clin. Allerg. 15 (1985) 311-320.